Derek J. Maetzold - Aug 3, 2021 Form 4 Insider Report for CASTLE BIOSCIENCES INC (CSTL)

Signature
/s/ Greg Acosta, Attorney-in-fact
Stock symbol
CSTL
Transactions as of
Aug 3, 2021
Transactions value $
-$282,807
Form type
4
Date filed
8/6/2021, 04:07 PM
Previous filing
Aug 3, 2021
Next filing
Aug 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CSTL Common Stock Sale -$94.3K -1.34K -0.88% $70.35 151K Aug 3, 2021 By DJM Grantor Retained Annuity Trust No. 1 F1, F2, F3
transaction CSTL Common Stock Sale -$94.3K -1.34K -0.76% $70.35 174K Aug 3, 2021 By The Maetzold Descendants 2020 Trust F1, F2, F4
transaction CSTL Common Stock Sale -$94.3K -1.34K -0.82% $70.35 162K Aug 3, 2021 By Derek Maetzold 2020 Irrevocable Trust F1, F2, F5
holding CSTL Common Stock 406K Aug 3, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were made pursuant to a Rule 10b5-1 plan adopted by DJM Grantor Retained Annuity Trust No. 1, The Maetzold Descendants 2020 Trust, and the Derek Maetzold 2020 Irrevocable Trust on June 15, 2021.
F2 These transactions were executed in multiple trades at prices ranging from $70.08 to $70.52, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Held by DJM Grantor Retained Annuity Trust No. 1 of which the Reporting Person is the trustee and beneficiary.
F4 Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
F5 Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.